STOCK TITAN
  1. Home
  2. News
  3. ARWR

Arrowhead Pharmaceuticals Inc. - ARWR STOCK NEWS

Welcome to our dedicated news page for Arrowhead Pharmaceuticals (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arrowhead Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arrowhead Pharmaceuticals's position in the market.

News
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, an investigational RNA interference therapeutic for complement mediated renal disease, such as IgAN. ARO-CFB aims to reduce hepatic expression of complement factor B, a key player in the activation of the alternative complement pathway. Pending clearance, Arrowhead intends to proceed with AROCFB-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-CFB in up to 66 healthy volunteers and patients with complement mediated kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
clinical trial
-
News
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT. The presentation will be available via webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
conferences
-
News
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced financial results for fiscal year 2023, including revenue of $240.7 million, operating loss of $205 million, and net loss of $209.3 million. The company presented positive Phase 2 clinical data for plozasiran and zodasiran, hosted a webinar featuring lipid and lipoprotein disorder experts, and completed encouraging chronic GLP toxicology for pulmonary candidates. Additionally, Arrowhead filed for regulatory clearance to initiate a Phase 1/2a study of ARO-DM1 for patients with type 1 myotonic dystrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.85%
Tags
earnings
News
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, an RNA interference therapeutic for type 1 myotonic dystrophy (DM1). ARO-DM1 aims to reduce the expression of the dystrophia myotonica protein kinase (DMPK) gene, addressing the lack of approved disease-modifying therapy for DM1. The company's Chief of Discovery and Translational Medicine, James Hamilton, M.D., MBA, highlighted the potential of ARO-DM1 in improving multiple symptoms, including muscle strength and function, for patients with DM1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
clinical trial
-
News
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
-
News
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal year ended September 30, 2023. Investors can access a live audio webcast on the Company's website and a replay will be available. Analysts can register for the conference call to receive the dial-in number and a personalized PIN code.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
conferences earnings
News
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented new Phase 2 clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3) at the AHA Scientific Sessions 2023. The data showed significant reductions in APOC3, triglycerides, and atherogenic lipoproteins in patients with severe hypertriglyceridemia and mixed dyslipidemia. The company plans to host a virtual analyst and investor event on November 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
clinical trial
-
News
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will be participating in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2023. The webcast of the presentation will be available on the Arrowhead website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
conferences
-
News
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
Rhea-AI Summary
Arrowhead Pharmaceuticals Inc. will present new Phase 2 clinical data from the SHASTA-2, MUIR, and ARCHES-2 studies at the American Heart Association Scientific Sessions 2023. The data will be discussed as potential treatments for severe hypertriglyceridemia and mixed dyslipidemia in patients with atherosclerotic cardiovascular disease. The company will also host a virtual analyst and investor event on November 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences clinical trial
News
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
Rhea-AI Summary
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will be participating in several upcoming events, including the 2023 Annual Northeast Amyotrophic Lateral Sclerosis Consortium Meeting, BMO Biopharma Spotlight Series, Cracking the Code: The Dawn of Nucleic Acid Medicines, and the 3rd International Research Conference on Neurodegenerative Diseases. Presentation materials can be accessed on the Arrowhead website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
conferences
Stock ARWR logo
Arrowhead Pharmaceuticals Inc.

Nasdaq:ARWR

ARWR Rankings

#1565 Ranked by Market Cap
#3965 Ranked by Stock Gains
N/A Ranked by Dividends

ARWR Stock Data

2.93B
118.95M
4.49%
66.68%
7.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Pasadena

About ARWR

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing